Orum Therapeutics, Inc. (KOSDAQ:475830)
South Korea · Delayed Price · Currency is KRW 120,000
+5,800 (5.08%)
Dec 30, 2025, 3:30 PM KST
Orum Therapeutics Company Description
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases.
The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor.
It also develops multiple programs; and E3 Ligase-DAC adaptor. The company was founded in 2016 and is headquartered in Daejeon, South Korea.
Orum Therapeutics, Inc.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Sung-Joo Lee |
Contact Details
Address: 281-25 Munji-ro Daejeon, 34050 South Korea | |
| Phone | 82 4 2716 3030 |
| Website | orumrx.com |
Stock Details
| Ticker Symbol | 475830 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7475830006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sung-Joo Lee | Chief Executive Officer |
| Martin Intae Jeong | Chief Financial Officer |